Patents by Inventor Ariel E. Feldstein

Ariel E. Feldstein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Detecting and Treating Liver Damage
    Publication number: 20150247149
    Abstract: The invention provides a method of detecting, monitoring, assessing and treating non-alcoholic fatty acid liver disease (NAFLD) and associated liver damage in a subject comprising measuring the amount of hepatocyte-derived circulating extracellular vesicles (EVs) and/or microparticle (MPs) in the bodily sample, or the expression level or activity of at least one biomarker expressed or detected in the EVs and/or MPs. The increased amount of EVs or MPs in the bodily sample and/or the increased expression or detection level of the biomarker of interest correlate with the degree or severity of NAFLD, NASH, liver fibrosis, or other associated liver damage, which can be associated with angiogenesis. Prevention and treatment of NAFLD, NASH, liver fibrosis or associated liver damage by reducing EVs or MPs, or targeting the biomarkers expressed in the EVs or MPs are also provided.
    Type: Application
    Filed: January 28, 2015
    Publication date: September 3, 2015
    Inventors: Ariel E. Feldstein, Akiko Eguchi
  • Detection and monitoring of liver damage
    Patent number: 8460943
    Abstract: A method of detecting liver damage in a subject comprises measuring the level of caspase-3 generated cytokeratin-18 fragments in the bodily sample. The level of measuring the level of caspase-3 generated cytokeratin-18 fragments is then correlated with liver disease progression.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: June 11, 2013
    Assignee: The Cleveland Clinic Foundation
    Inventors: Ariel E. Feldstein, Anna Wieckowska, Nizar Zein
  • Detection and monitoring of liver damage
    Patent number: 8409878
    Abstract: A method of detecting liver damage in a subject comprises measuring the level of caspase-3 generated cytokeratin-18 fragments in the bodily sample. The level of measuring the level of caspase-3 generated cytokeratin-18 fragments is then correlated with liver disease progression.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: April 2, 2013
    Assignee: The Cleveland Clinic Foundation
    Inventors: Ariel E. Feldstein, Anna Wieckowska, Nizar Zein
  • DETECTION AND MONITORING OF NONALCOHOLIC FATTY LIVER DISEASE
    Publication number: 20130056630
    Abstract: A method of assessing the severity of nonalcoholic fatty liver disease nonalcoholic steatohepatitis, and/or liver fibrosis in a subject includes obtaining a bodily sample from a subject and determining a level of the at least one oxidized fatty acid product in the sample. An increased level of at least one oxidized fatty acid product in the subject compared to a control is indicative of an increase in severity of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and/or liver fibrosis.
    Type: Application
    Filed: May 3, 2011
    Publication date: March 7, 2013
    Applicant: THE CLEVELAND CLINIC FOUNDATION
    Inventors: Ariel E. Feldstein, Stanley L. Hazen
  • DETECTION AND MONITORING OF LIVER DAMAGE
    Publication number: 20110244490
    Abstract: A method of detecting liver damage in a subject comprises measuring the level of caspase-3 generated cytokeratin-18 fragments in the bodily sample. The level of measuring the level of caspase-3 generated cytokeratin-18 fragments is then correlated with liver disease progression.
    Type: Application
    Filed: December 28, 2010
    Publication date: October 6, 2011
    Inventors: Ariel E. Feldstein, Anna Wieckowska, Nizar Zein
  • DETECTION AND MONITORING OF LIVER DAMAGE
    Publication number: 20110151488
    Abstract: A method of detecting liver damage in a subject comprises measuring the level of caspase-3 generated cytokeratin-18 fragments in the bodily sample. The level of measuring the level of caspase-3 generated cytokeratin-18 fragments is then correlated with liver disease progression.
    Type: Application
    Filed: December 28, 2010
    Publication date: June 23, 2011
    Inventors: Ariel E. Feldstein, Anna Wieckowska, Nizar Zein
  • Detection and monitoring of liver damage
    Patent number: 7883904
    Abstract: A method of detecting liver damage in a subject comprises measuring the level of caspase-3 generated cytokeratin-18 fragments in the bodily sample. The level of measuring the level of caspase-3 generated cytokeratin-18 fragments is then correlated with liver disease progression.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: February 8, 2011
    Assignee: The Cleveland Clinic Foundation
    Inventors: Ariel E. Feldstein, Anna Wieckowska, Nizar Zein